Novartis India Share Price

Novartis India Investment Rating

• Master Rating:

• Novartis India has an operating revenue of Rs. 422.68 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of -1% needs improvement, ROE of -0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 200DMA and around 8% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 26 which is a POOR score indicating inconsistency in earnings, a RS Rating of 46 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 105 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.